NewsEvents

Your Yourlocation: Home > Observe the effect of Symbicort turbuhaler combined with tiotropium bromide(136310-93-5) for the treatment of  chronic obstructive pulmonary disease in stable stage

Objective: To observe the effect of Symbicort turbuhaler combined with tiotropium bromide(136310-93-5) for the treatment of chronic obstructive pulmonary disease in stable stage. Methods: Sixty patients with midrange-severe COPD who were recruited in the hospital and were made correct diagnosises were randomly divided into 2 groups:control  group  and treatment group. Control group were given  tiotropium bromide(136310-93-5), inhaling 18ug each time once daily;additionally,treatment group were combined with Symbicort turbuhaler (160/4.5ug),one inhalation each time twice daily. Lung function, blood gas analysis and the decreased times of acute exacerbate of pre-treatment and post-treatment were observed. Results: The indexes of lung function, blood gas analysis and the times of acute exacerbation in treatment group were all significantly superior to those in control group (P<0.05). Conclusion: Symbicort turbuhaler(160/4.5ug) combined with tiotropium bromide(136310-93-5) could improve Lung function, blood gas analysis in patients with COPD in stable stage and decrease the times of acute exacerbation. 

Chronic obstructive pulmonary disease (COPD) is an airway chronic inflammatory disease characterized by progressive aggravated, incomplete reversible airflow limitation. In this study, we combined the effects of tiotropium bromide and prednisone on the clinical efficacy of 60 patients with moderate to severe remission in COPD.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved